sur GENSIGHT BIOLOGICS S.A. (EPA:SIGHT)
Crossing thresholds for GENSIGHT BIOLOGICS SA
On May 22, 2024, GENSIGHT BIOLOGICS SA received a threshold crossing declaration from the American company Armistice Capital, LLC. The latter, acting on behalf of the Armistice Capital Master Fund Ltd., crossed the thresholds of 5% of the company's capital and voting rights on May 9, 2024.
On this date, Armistice Capital held 6,329,113 GENSIGHT BIOLOGICS SA shares, representing 6.21% of the capital and voting rights. This crossing results from the subscription to a capital increase of the company.
As of May 22, 2024, Armistice Capital reported holding 6,292,000 GENSIGHT BIOLOGICS SA shares, or 6.18% of the capital and voting rights. In addition, it has 6,329,113 share subscription warrants exercisable until November 9, 2026, offering the right to as many shares at a unit price of €0.45.
R. P.
Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de GENSIGHT BIOLOGICS S.A.